Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo
Open accessAbstract
Erythropoiesis is critically dependent on erythropoietin (EPO), a glycoprotein hormone that is regulated by hypoxia-inducible factor (HIF). Hepatocytes are the primary source of extrarenal EPO in the adult and express HIF-1 and HIF-2, whose roles in the hypoxic induction of EPO remain controversial. In order to define the role of HIF-1 and HIF-2 in the regulation of hepatic EPO expression, we have generated mice with conditional inactivation of Hif-1alpha and/or Hif-2alpha (Epas1) in hepatocytes. We have previously shown that inactivation of the von Hippel-Lindau tumor suppressor pVHL, which targets both HIFs for proteasomal degradation, results in increased hepatic Epo production and polycythemia independent of Hif-1alpha. Here we show that conditional inactivation of Hif-2alpha in pVHL-deficient mice suppressed hepatic Epo and the development of polycythemia. Furthermore, we found that physiological Epo expression in infant livers required Hif-2alpha but not Hif-1alpha and that the hypoxic induction of liver Epo in anemic adults was Hif-2alpha dependent. Since other Hif target genes such phosphoglycerate kinase 1 (Pgk) were Hif-1alpha dependent, we provide genetic evidence that HIF-1 and HIF-2 have distinct roles in the regulation of hypoxia-inducible genes and that EPO is preferentially regulated by HIF-2 in the liver.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The observed downregulation of EPO in Hep3b cells by YC-1 suggests that YC-1 also inhibits HIF-2 activity.
“Bearing in mind that EPO is a specific HIF-2 target (Rankin et al., 2007), the observed downregulation of EPO in Hep3b cells by YC-1 suggests that YC-1 also inhibits HIF-2 activity.”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Rankin et al., 2007
Cell type-specific inactivation of VHL in hepatocytes resulted in HIF-2-, but not HIF-1-dependent erythrocytosis.
“Cell type-specific inactivation of the VHL-E3 ubiquitin ligase in hepatocytes resulted in HIF-2-, but not in HIF-1-dependent erythrocytosis”
From Regulation of erythropoiesis by hypoxia-inducible factors (2013) · cites this paper as [72]
Pharmacological PHD inhibition caused a HIF-2-dependent increase in liver Epo mRNA levels.
“while pharmacological PHD inhibition caused a HIF-2-dependent increase in liver Epo mRNA levels. 72”
From Regulation of erythropoiesis by hypoxia-inducible factors (2013) · cites this paper as [72]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 70 · Cited by 596
- Authors
- Rankin, E. B., Biju, M. P., Liu, Q., Unger, T. L., Rha, J., Johnson, R. S., Simon, M. C., Keith, B., & Haase, V. H.
- Affiliations
- University of Pennsylvania (US)
- University of California San Diego (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Haase, Volker H.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-04-02
- Volume
- 117
- Issue
- 4
- Pages
- 1068-1077
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1838939
- OpenAlex
- W2142622000
- Cited by
- 596
- References
- 70
- Citations by year
- 2026: 24 · 2025: 24 · 2024: 21 · 2023: 29 · 2022: 23 · 2021: 32 · 2020: 28 · 2019: 25 · 2018: 19 · 2017: 23 · 2016: 37 · 2015: 30 · 2014: 26 · 2013: 29 · 2012: 32
- FWCI
- 31.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- GlaxoSmithKline
- National Institutes of Health
- National Cancer Institute (CA100787, R01CA100787)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK073467, R21DK073467, P30DK50306, P30DK050306)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hemoglobin structure and function
- Keywords
- HIF-2, HIF-1α, erythropoietin, hepatocytes, polycythemia, VHL, conditional gene inactivation, anemia, PGK1
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Animals, Disease Models, Animal, Erythropoietin, Gene Expression Regulation, von Hippel-Lindau Disease, Liver, Polycythemia Vera, Mice, Knockout, Hepatocytes, Mice, Basic Helix-Loop-Helix Transcription Factors, Basic Helix-Loop-Helix Proteins, Von Hippel-Lindau Tumor Suppressor Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review